Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N‐desisopropylation is mediated mainly by CYP1A2.

British Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1995, Pages 421-431

  Yoshimoto, K ^a   Echizen, H ^a   Chiba, K ^a   Tani, M ^a   Ishizaki, T ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ETHOXYRESORUFIN; MEPHENYTOIN; PROPRANOLOL; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL;

AGED; BENZOFLAVONES; CYTOCHROME P-450 ENZYME SYSTEM; DESIPRAMINE; DITIOCARB; FEMALE; HUMAN; HYDROXYLATION; IN VITRO; ISOENZYMES; MALE; MEPHENYTOIN; MICROSOMES, LIVER; MIDDLE AGE; OXAZINES; PHENACETIN; PROPRANOLOL; QUINIDINE; RECOMBINANT PROTEINS; STEREOISOMERISM; SUBSTRATE SPECIFICITY; SULFAPHENAZOLE; SUPPORT, NON-U.S. GOV'T; TOLBUTAMIDE; TROLEANDOMYCIN;

EID: 0028956887     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1995.tb04472.x     Document Type: Article

References (48)

1. Quantitative account of propranolol metabolism in urine of normal man
2. Propranolol oxidation by human liver microsomes — the use of cumene hydroperoxide to probe isoenzyme specificity and regio‐ and stereoselectivity
3. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol
4. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
5. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects
6. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities
7. Genetic polymorphism of S‐mephenytoin hydroxylation
8. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
9. Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
10. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites
11. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P‐450 in metoprolol oxidation by human liver microsomes
12. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S‐mephenytoin 4′‐hydroxylation
13. Validation and use of cloned, expressed human drug‐metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug‐drug interactions
14. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4‐hydroxy propranolol
15. Stereoselective disposition and glucuronidation of propranolol in humans
16. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias
17. Stereoselective haemodynamic effects of R‐ and S‐propranolol in man
18. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P‐450 human‐2
19. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono‐N‐dealkylation metabolism of disopyramide with human liver microsomes
20. Protein measurement with the Folin phenol reagent
21. MP) activity in human liver sampls obtained as surgical waste from Japanese patients
22. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2
23. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
24. Separation of human liver microsomal tolbutamide hydroxylase and S‐mephenytoin 4‐hydroxylase cytochrome P450 enzymes
25. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S‐mephenytoin 4′‐hydroxylation
26. Evidence that CYP2C19 is the major (S)‐mephenytoin 4′‐hydroxylase in humans
27. The major genetic defect responsible for the polymorphism of S‐mephenytoin metabolism in humans
28. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
29. Human p450PCN1. Sequence, chromosomal localization, and direct evidence through cDNA expression that p450PCNl is nifedipine oxidase
30. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines
31. The specificity of inhibition of debrisoquine 4‐hydoxylase activity by quinidine and quinine is the inverse of that in man
32. Role of human P‐450 2E1 in the oxidation of many low molecular weight cancer suspects
33. Identification of an inducible form of cytochrome P‐450 in human liver
34. The role of S‐mephenytoin 4′‐hydroxylase in imipramine metabolism by human liver microsomes: a two‐enzyme kinetic analysis of N‐demethylation and 2‐hydroxylation
35. Impairment of debrisoquine 4‐hydroxylase and related monooxygenase activities in the rat following treatment with propranolol
36. Regio‐ and stereoselective propranolol metabolism by 15 forms of purified cytochrome P‐450 from rat liver
37. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization
38. In vitro inhibition studies of two isozymes of human liver cytochrome P450‐mephenytoin p‐hydroxylase and sparteine monooxygenase
39. N‐Dealkylation of propranolol: Trapping of the 3‐(1‐naphthoxy)‐2‐hydroxypropionaldehyde formed in rat liver microsomes
40. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man
41. Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade
42. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin
43. Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine
44. Major pathway of imipramine metabolism is catalyzed by cytochrome P‐450 1A2 and P‐450 3A4 in human liver
45. Atypical metabolism of deprenyl and its enantiomer, (S)‐(+)‐N,α‐dimethyl‐N‐propynylphenethylamine, by cytochrome P450 2D6
46. Oxidation of (R)‐and (S)‐propranolol in human and dog liver microsomes. Species differences in stereoselectivity
47. Stereoselective oxidative metabolism of propranolol in the microsomal fraction from rat and human liver. Use of deuterium labeling and pseudoracemic mixtures
48. N‐Dealkylation of propranolol in rat, dog and man — Chemical and stereochemical aspects